Skip to main content
OpenTrials
Completed

NCT Number: NCT00113867

Effects of Hormonal Infertility Treatment on Cognition in Pre-Menopausal Women

The purpose of this study is to examine the effects of marked alterations in ovarian steroid hormones on cognitive functions in women. Sex hormones and stress hormones of women awaiting or undergoing in-vitro fertilization (IVF) will be compared with levels of women adopting children and women on oral contraceptives.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year and older

Sex eligibility

Female

Study type

Observational

Primary location

National Institute on Aging (NIA), Harbor Hospital

Baltimore, Maryland, 21225, United States

About this study

Much of our understanding of the effects of ovarian steroid hormones on cognitive functioning comes from studies of changes in cognitive function associated with hormone replacement therapy (HRT) in post-menopausal women and changes in menstrual cycle phase in premenopausal women. If fluctuations in ovarian sex steroid hormone levels across the normal physiological range affect cognitive functions in women, then marked alterations in hormone levels should have a notable effect on cognitive function.

Hormonal in-vitro fertilization (IVF) treatments for female infertility result in dramatic fluctuations in estrogen levels. Women awaiting infertility treatment report negative emotions, depressed mood, declines in memory and concentration, and higher levels of reported stress compared to women who have never experienced infertility.

Four groups of twenty women each will be recruited for this observational study:

  • Group 1 - IVF treatment with GnRH-a alone
  • Group 2 - IVF treatment with GnRH-a plus sex steroid stimulating hormones
  • Group 3 - ADPT control (women in the process of adopting children)
  • Group 4 - OC (oral contraceptives) control

All groups will receive a cognitive/affect assessment twice, with a 3-week interval between assessments. Blood and salivary samples will be taken on the two test days to measure ovarian sex steroid hormone levels and stress hormone levels. Salivary samples will also be taken on a third day in between the two test days. Heart Period Variability (HPV), a measure of cardiac functioning, will be measured using electrocardiogram (ECG).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women 25 years and older, who are still ovulating
  • Residing in Maryland or the Washington DC metropolitan area
  • Healthy women in one of the following groups:
  • 1) beginning or currently undergoing IVF infertility treatments with GnRH-a alone,
  • 2) beginning or currently undergoing IVF infertility treatments with GnrH-a plus sex steroid stimulating hormones,
  • 3) going through the adoption process, or
  • 4) taking monophasic oral contraceptives for at least six months

Exclusion criteria

  • English not the primary language
  • Women who are peri- or post-menopausal
  • Women who are currently taking anti-depressants or have a history of head injury or neurological/psychiatric condition
  • Groups 1 & 2 (IVF) - women who are undergoing Inter-uterine insemination as an infertility treatment
  • Group 3 (ADPT) - women who underwent hormonal infertility treatments within the previous 6 months
  • Group 4 (OC) - women on progesterone only (mini-pill) oral contraceptives

Sponsors and collaborators

Lead sponsor

National Institute on Aging (NIA)

Nih

Registry information

Important dates

Study start
2003
Primary completion
2006
Study completion
2006
First posted
Jun 13, 2005
Registry last updated
Dec 11, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.